228 related articles for article (PubMed ID: 12380950)
21. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma.
Gerull S; Goerner M; Benner A; Hegenbart U; Klein U; Schaefer H; Goldschmidt H; Ho AD
Bone Marrow Transplant; 2005 Dec; 36(11):963-9. PubMed ID: 16184182
[TBL] [Abstract][Full Text] [Related]
22. [Allogeneic hematopoietic stem cell transplantation for multiple myeloma].
Takase K; Miyamoto T
Nihon Rinsho; 2015 Jan; 73(1):107-13. PubMed ID: 25626314
[TBL] [Abstract][Full Text] [Related]
23. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
Novitzky N; Thomas V; du Toit C
Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
[TBL] [Abstract][Full Text] [Related]
24. New questions about transplantation in multiple myeloma.
Hari P; Pasquini MC; Vesole DH
Oncology (Williston Park); 2006 Sep; 20(10):1230-42; discussion 1242, 1244, 1249-50. PubMed ID: 17024872
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
26. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
[TBL] [Abstract][Full Text] [Related]
27. New approaches to treating malignances with stem cell transplantation.
Margolis J; Borrello I; Flinn IW
Semin Oncol; 2000 Oct; 27(5):524-30. PubMed ID: 11049020
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma.
Danylesko I; Shimoni A; Nagler A
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S330-48. PubMed ID: 24290219
[TBL] [Abstract][Full Text] [Related]
30. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
[TBL] [Abstract][Full Text] [Related]
31. Progress in allogeneic transplantation for multiple myeloma.
Gahrton G
Eur J Haematol; 2010 Oct; 85(4):279-89. PubMed ID: 20608964
[TBL] [Abstract][Full Text] [Related]
32. [Stem cell transplantation in multiple myeloma].
Fukuda S; Sunami K; Sezaki T
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1407-14. PubMed ID: 10500527
[TBL] [Abstract][Full Text] [Related]
33. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
[TBL] [Abstract][Full Text] [Related]
34. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
35. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic bone marrow transplantation in multiple myeloma.
Gahrton G
Pathol Biol (Paris); 1999 Feb; 47(2):188-91. PubMed ID: 10192887
[TBL] [Abstract][Full Text] [Related]
37. [Hematopoietic stem cell transplantation in multiple myeloma].
Vela-Ojeda J; Ruiz-Esparza MA
Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
[TBL] [Abstract][Full Text] [Related]
38. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report.
Rondelli D; Bandini G; Cavo M; Re F; Motta M; Senese B; Leopardi G; Stanzani M; Tura S
Bone Marrow Transplant; 1999 Sep; 24(6):685-7. PubMed ID: 10490737
[TBL] [Abstract][Full Text] [Related]
39. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
Vesole DH; Simic A; Lazarus HM
Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
[TBL] [Abstract][Full Text] [Related]
40. Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion?
Peggs K; Mackinnon S
Leukemia; 2004 Sep; 18(9):1541-2; author reply 1542-3. PubMed ID: 15241439
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]